Stifel (SF)
NYSEFinancialsInvestment - Banking & Investment ServicesSnapshot 2026-09-14
$77.97-2.24%
Close 2026-09-14 · 1-day change
NYSEFinancialsInvestment - Banking & Investment ServicesSnapshot 2026-09-14
Research Workspace
Put SF beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Investment Banking & Brokerage is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Increase revenue by 30%-40% vs 2025-Q1: 13.0% vs 30% target.
View ThesisRevenue growth is accelerating — up about 11% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskSF's growth depends on increasing revenue by 30%-40% versus its 2025-Q1 target. Revenue grew 13% year over year, and the last quarter beat expectations. It trades at 13.5× P/E versus a peer median of 21.8×, indicating modest expectations compared to our view. The primary risk is the need to meet revenue targets, as the current trajectory is below the goal. Peer multiples imply a price roughly in line with where it trades (about fair). The thesis has broken due to the primary pillar being revenue growth below target.
Trailing returns as of 2026-09-14. SF is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering SF (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare SF with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SF Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Investment Banking & Brokerage — fair value, gap to price, and forward P/E.
Compare the value case
Put SF next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Grow revenue and investment banking momentum
Appointment enhances investment banking momentum and revenue growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase client assets and fee-based assets
Client assets increased significantly, supporting growth objectives.
Advances: Maintain and grow earnings per share
Earnings beat indicates strong performance and growth potential.
Advances: Maintain and grow earnings per share
Upgrade indicates positive outlook for earnings growth.
Advances: Grow revenue and investment banking momentum
Analyst upgrade indicates positive earnings outlook.
Advances: Maintain and grow earnings per share
Earnings highlight competitive advantage in AI investment banking.
Advances: Grow revenue and investment banking momentum
Custom Health's pharmacy deal enhances investment banking momentum.
Advances: Grow revenue and investment banking momentum
Targets significant loan growth and net interest income.
